Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder

Guy M. Goodwin, MD ; Ania Nowakowska, MSc ; Merve Atli, MSc ; Boadie W. Dunlop, MD ; David Feifel, MD, PhD ; David J. Hellerstein, MD ; Lindsey Marwood, PhD ; Zainib Shabir, MSc ; Sunil Mistry, MSc ; Susan C. Stansfield, PhD ; Emma Teoh, MSc ; Joyce Tsai, PhD ; Matthew B. Young, PhD ; Ekaterina Malievskaia, MD

J Clin Psychiatry 2025;86(1):24m15449

Abstract

Background: The largest randomized study of psilocybin to date demonstrated the efficacy of COMP360 25 mg (Compass Pathways’ investigational proprietary pharmaceutical-grade synthesized psilocybin formulation) in participants with treatment-resistant depression (COMP 001), compared with 10 mg and 1 mg doses. Here, we report findings from COMP 004, a 52-week observational follow-up of patients from COMP 001 and COMP 003, a small open-label study of the coadministration of 25 mg COMP360 with continuing antidepressant treatment.

Methods: Adverse events (AEs) were collected over the full 52-week period. The primary efficacy endpoint was time to a prespecified depressive event over the 52 weeks following COMP360 administration in COMP 001 participants, presented as Kaplan-Meier estimates. A post hoc analysis included only participants that entered COMP 004. Data were collected from July 2020 to July 2022.

Results: Sixty-six participants entered COMP 004 (COMP 001, n = 58 [25 mg group n = 22, 10 mg group n = 19, 1 mg group n = 17]; COMP 003, n = 8). Few AEs were reported post-entry into COMP 004, with 1 AE of mild suicidal ideation in the 1 mg group deemed possibly related to study drug. For all COMP 001 patients (n = 233), median time to depressive event was greater for the 25 mg group (92 days) compared to the 10 mg (83 days) and 1 mg (62 days) groups, with the majority of participants having had a depressive event by Week 12 (25 mg n = 37/75, 10 mg n = 38/79, 1 mg n = 44/75). The post hoc supplementary analysis of those who enrolled in COMP 004 from COMP 001 exhibited the difference between groups more strikingly (25 mg, 189 days; 10 mg, 43 days; 1 mg, 21 days); however, only 10 participants experienced a depressive event post-COMP 004 enrollment (25 mg n = 6, 10 mg n = 3, 1 mg n = 1) from COMP 001 and none from COMP 003. At COMP 004 entry, the 1 mg group had the highest number of participants on antidepressant medication (n = 10; 10 mg, n = 9; 25 mg, n = 6) and generally initiated treatment earlier.

Conclusion: Over 52 weeks, a single administration of 25 mg psilocybin suggested longer maintenance of antidepressant effect than both 1 mg and 10 mg. Larger long-term studies are required to confirm these findings and provide clarity on the longer-term effects of psilocybin.

Trial Registration: ClinicalTrials.gov identifier: NCT04519957.

J Clin Psychiatry 2025;86(1):24m15449

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (17)

McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394–412. PubMed CrossRef
Brown S, Rittenbach K, Cheung S, et al. Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews. Can J Psychiatry. 2019;64(6):380–387. PubMed CrossRef
Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52(suppl):28–34. PubMed
Moriarty AS, Coventry PA, Hudson JL, et al. The role of relapse prevention for depression in collaborative care: a systematic review. J Affect Disord. 2020;265:618–644. PubMed CrossRef
Corral R, Alessandria H, Agudelo Baena LM, et al. Suicidality and quality of life in treatment-resistant depression patients in Latin America: secondary interim analysis of the TRAL study. Front Psychiatry. 2022;13:812938. PubMed CrossRef
Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171–1180. PubMed CrossRef
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMed CrossRef
Pigott HE, Kim T, Xu C, et al. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR* D study’s patient-level data with fidelity to the original research protocol. BMJ open. 2023;13(7):e063095. PubMed
Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment resistant episode of major depression. N Engl J Med. 2022;387(18):1637–1648. PubMed CrossRef
Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord. 2023;327:120–127. PubMed CrossRef
Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411. PubMed CrossRef
Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489.
Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235(2):399–408. PubMed CrossRef
Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151–158. PubMed CrossRef
Tai SJ, Nielson EM, Lennard-Jones M, et al, Development and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research. Front Psychiatry. 2021;12:586682. PubMed CrossRef
Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023;48(10):1492–1499. PubMed CrossRef
Martinotti G, Santacroce R, Pettorruso M, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018;8(3):47. PubMed CrossRef